Successful, we will replay to you quickly.

OK

Your message is being sent, please wait.

Close

test

Close

Send mail failed, please send again!

Close

Products are for research use only. Not for human use. We do not sell to patients.

Signaling Pathway

Selumetinib

HY-50706

(AZD6244; Array142886; ARRY-142886; AZD-6244)

Selumetinib
Selumetinib Chemical Structure

Selumetinib (AZD6244; ARRY-142886) is a potent, highly selective MEK1 inhibitor with IC50 of 14 nM, also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc.

Price and Availability of Selumetinib
We offer a substantial discount on larger orders.Inquiry for price and availability only. Please place your order via our email or fax.
Inquiry Online Contact Us
Selumetinib Data Sheet

View current batch:

Purity: 99.46%

Selumetinib

Related Products

PDF File 1.64MB

Recommended Products

MORE

Biological Activity of Selumetinib

Selumetinib (AZD6244; ARRY-142886) is a potent, highly selective MEK1 inhibitor with IC50 of 14 nM, also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc.
IC50 value: 14 nM [1]
Target: MEK1
in vitro: ZD6244 is not competitive with ATP and inactivates the ERK1/2 phosphorylation with IC50 concentrations below 40 nM. AZD6244 also inhibits the growth of primary HCC cells through inhibition of ERK1/2 and p90RSK phosphorylation, accompanied with elevation of the cleavage of caspase-3 and caspase-7, and cleaved poly(ADP)ribose polymerase. AZD6244 has little effects on the p38, c-Jun-NH2-kinase, phosphatidylinositol 3-kinase, and MEK5/ERK5 pathways [1]. AZD6244 is sensitive to Raf mutations in breast cancer cell lines and Ras mutations in NSCLC cell lines [2].
in vivo: AZD6244 significantly inhibits phosphorylation of ERK1/2 in 2-1318, 5-1318, 26-1004 and 4-1318 xenografts and induces apoptosis in primary 2-1318 cells by activating the caspase pathway [1]. AZD6244 could inhibit the tumor growth in HT-29 xenograft, which is a colorectal tumor model carrying a B-Raf mutation, at a dose of 100 mg/kg and the tumor growth inhibition of AZD6244 is better than it of Gemcitabine [3].

Clinical Information of Selumetinib

MORE

[1]. Huynh H, et al, Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol Cancer Therapy, 2007, 6 (1), 138-146
[2]. Garon EB, et al. Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines. Mol Cancer Thera, 2010, 9 (7), 1985-1994.
[3]. Yeh TC, et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res, 2007, 13 (5), 1576-1583.

Products are for research use only. Not for human use. We do not sell to patients.

Keywords: buy Selumetinib | Selumetinib Supplier | purchase Selumetinib | Selumetinib cost | Selumetinib manufacturer | order Selumetinib | Selumetinib distributor | Selumetinib structure buy 606143-52-6 | 606143-52-6 Supplier | purchase 606143-52-6 | 606143-52-6 cost | 606143-52-6 manufacturer | order 606143-52-6 | 606143-52-6 distributor | 606143-52-6 structure